Monopar Therapeutics Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 9, 2024. Monopar is a clinical-stage radiopharmaceutical company with no approved products or product revenue.
Business context and outlook
The company is prioritizing MNPR-101 radiopharmaceutical programs: MNPR-101-Zr, an imaging agent in a Phase 1 trial, and MNPR-101-RIT, a therapeutic candidate in preclinical development. The Phase 1 MNPR-101-Zr trial in Australia was active and recruiting by April 10, 2024. Management targeted MNPR-101-RIT’s first clinical trial for Q4 2024 or Q1 2025. Monopar plans to wind down its camsirubicin Phase 1b trial and MNPR-202 preclinical work in Q2 2024.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $966,110 | $1,653,369 |
| General and administrative expense | $757,281 | $871,675 |
| Total operating expenses / operating loss | $1,723,391 | $2,525,044 |
| Interest income | $82,165 | $90,488 |
| Net loss | $1,641,226 | $2,434,556 |
| Basic and diluted loss per share | $0.10 | $0.19 |
| Cash used in operating activities | $1,655,423 | $2,271,113 |
Revenue and profit margins are not applicable because Monopar has no product revenue and remains loss-making. At March 31, 2024, cash and cash equivalents were $7.81 million and investments were $0.99 million, totaling approximately $8.79 million. Total liabilities were $1.44 million, all current accounts payable, accrued expenses and other current liabilities; the filing reports no debt. Stockholders’ equity was $7.48 million and accumulated deficit was $61.85 million.
Management stated that available funds were expected to support planned operations at least through June 30, 2025, while also anticipating a need to raise additional capital within 12 months. The company reported no substantial doubt about its ability to continue as a going concern based on its assessment through June 2025. This runway estimate depends on assumptions and may prove shorter.
Material changes versus the prior period
- Operating expenses fell by $802,000 and net loss narrowed by $793,330 year over year. R&D expense decreased by $687,000, primarily because Validive trial costs ended after its March 2023 closure. G&A expense decreased by $115,000, mainly due to lower stock-based compensation and patent costs.
- Operating cash use declined by $616,000, while financing cash inflows increased by $2.38 million. Net cash increased by $541,499 in Q1 2024, compared with a $2.46 million decrease in Q1 2023.
- Monopar sold 2,545,305 shares through its at-the-market program for net proceeds of $3.19 million, at an average gross price of $1.29 per share. Shares outstanding increased from 14,904,497 at year-end to 17,484,175 at March 31.
- Management shifted resources toward radiopharmaceuticals and away from camsirubicin and MNPR-202, concentrating the company’s development portfolio and associated risks.
Risks, contingencies and other notable items
- Financing and dilution: Continued development requires additional funding or suitable collaborations. Equity financing may dilute existing holders; the company may need to delay, reduce or terminate programs if funding is unavailable.
- Nasdaq listing: The stock bid price remained below the $1.00 minimum. Nasdaq granted an additional 180-day compliance period on February 27, 2024, with a deadline of August 26, 2024. Failure to comply could lead to delisting; a reverse split or appeal may be considered, with uncertain effects.
- Development and operating risks: Clinical and regulatory outcomes, patient enrollment, third-party manufacturing and trial execution, radioisotope availability, supply-chain logistics, competition and the novel nature of radiopharmaceuticals create material uncertainties.
- License obligation: XOMA milestones for MNPR-101 could total up to $14.925 million if achieved; no milestone had been reached as of the filing. The first payment is tied to first dosing in a Phase 2 trial.
- Legal and controls: The company reported no asserted legal claims or material adverse legal proceedings. Management concluded disclosure controls were effective as of March 31, 2024 and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the company secures additional financing or a collaboration on acceptable terms, and whether the stated cash runway remains achievable.
- Progress, enrollment and emerging data from the MNPR-101-Zr Phase 1 trial, and whether MNPR-101-RIT enters clinical testing on the stated timeline.
- Whether Monopar regains Nasdaq’s $1.00 bid-price compliance by August 26, 2024, and any effect of a reverse split or delisting risk.
- Execution and cost of winding down camsirubicin and MNPR-202, and the resulting effect on cash use, program focus and financing prospects.
- Future share issuance and dilution, including use of the Capital on Demand sales agreement.